Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | MGAM | O43451 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SI | P14410 | 2/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206205 | 0.85 | NOTUM (0.73) | NOTUMHDAC1CYP19A1MGAMGAA | |
| SCHEMBL2820182 | 0.85 | NOTUM (0.73) | NOTUMHDAC1CYP19A1 | |
| SCHEMBL12885309 | 0.85 | NOTUM (0.73) | NOTUMHDAC1CYP19A1HSP90AB1 | |
| SCHEMBL2494737 | 0.84 | NOTUM (0.73) | NOTUMHDAC1CYP19A1HSP90AB1KCNMA1 | |
| SCHEMBL3650120 | 0.84 | NOTUM (0.72) | NOTUMHDAC1HSP90AB1 | |
| SCHEMBL28863788 | 0.83 | NOTUM (0.71) | NOTUMKDM4EMAPTCYP19A1HSP90AB1 | |
| SCHEMBL2820279 | 0.82 | NOTUM (0.69) | NOTUMHDAC1CYP19A1HSP90AB1 | |
| SCHEMBL2821391 | 0.81 | NOTUM (0.68) | NOTUMMAPTHDAC1CYP19A1HSP90AB1 | |
| SCHEMBL2819423 | 0.81 | NOTUM (0.68) | NOTUMHDAC1CYP19A1MGAMGAA | |
| SCHEMBL13573693 | 0.81 | CYP19A1 (0.70) | NOTUMHDAC1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-6566376-B1 | For therapy of chemokine receptor related diseases and conditions such as rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA UK LIMITED (GB) | 2003-05-20 | — | — | US | disclosed |
| EP-1202984-B1 | DIPHENYL-PIPERIDINE DERIVATE | ASTRAZENECA UK LTD (GB) | 2003-03-05 | — | — | EP | disclosed |
| EP-1202984-A1 | NOVEL DIPHENYL-PIPERIDINE DERIVATE | AstraZeneca UK Limited (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005782-A1 | NOVEL DIPHENYL-PIPERIDINE DERIVATE | ASTRAZENECA UK LIMITED (GB) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885KDM4E 3907/4885MAPT 1431/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885KDM4E 4149/4885MAPT 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.